Polymorphids an mRNA Expression in Obese Genes

Polymorphism Clinical Trial

Official title:

Polymorphids and mRNA Expression in Genes, Significant for Developing Obesity and Typ II Diabetes in Different Types/Localisations of Fat Tissue

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01708083
• Other study ID #: 2009/1629-31/3
• Status: Completed
• Phase: N/A
• First received: October 9, 2012
• Last updated: August 21, 2013
• Start date: January 2010
• Est. completion date: February 2013

Study information

• Verified date: August 2013
• Source: Karolinska Institutet
• Contact: n/a
• Is FDA regulated: No
• Health authority: Sweden: The National Board of Health and Welfare
• Study type: Observational

Clinical Trial Summary

Fat tissue from omenta, thigh and abdomen taken under anesthesia on subjects undergoing laparoscopic surgery, cholecystectomy, reflux surgery or gastric by-pass (GBP).

Are there any difference in polymorphids and/or mRNA expression in genes significant for developing obesity, between normal weight and obese individuals, with or without diabetes typ 2 .

Are there any difference in polymorphids and/or mRNA expression in different types of fat tissue

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: February 2013
• Est. primary completion date: February 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• age 18 years or older

• laparoscopic surgery (Gastric by-pass, cholecystectomy, antireflux surgery)

• Normal weight without type 2 diabetes BMI 18-25

• Obese without type 2 diabetes BMI>35

• Obese with type 2 diabetes BMI>35

Exclusion Criteria:

• under 18 years

• open surgery

• pregnancy

• BMI >27-<35

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• mRNA Expression
• Polymorphism

Locations

Country	Name	City	State
Sweden	Ersta hospital	Stockholm	Stockholm County Council
Sweden	Karolinska Institutet, CMM	Stockholm

Sponsors (1)

Lead Sponsor	Collaborator
Karolinska Institutet

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Differences in polymorphids and/or mRNA expression in genes, significant for developing obesity and type 2 diabetes, between patients with normal weight and obesity	fat biopsy taken from abdomen, omenta and thigh at surgery	approximatly 30 minutes after start of operation	No
Primary	Difference in polymorphids and/or mRNA expression in different types of fat tissue in patients with normal weight or obesity with or without diabetes type 2	fat biopsy; abdomen, omenta and thigh taken at surgery	approximatly 30 minutes after start of operation	No